- [Resource Hub](/)
- [Publication](/?resource-type=publication#library)
- Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score

# Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score

He M, Chan NNN, Liu M, Robbins CJ, Bates K, Benanto J, et al.

Applied Immunohistochemistry & Molecular Morphology . 2026;34(3):143-154. DOI [10.1097/pai.0000000000001311](https://doi.org/10.1097/pai.0000000000001311). PMID 41709478. PMCID PMC13143368.

How to cite

### AMA

He M, Chan NNN, Liu M, Robbins CJ, Bates K, Benanto J, et al. Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. Appl Immunohistochem Mol Morphol . 2026;34(3):143-154. doi:10.1097/pai.0000000000001311

### APA

He, M., Chan, N. N. N., Liu, M., Robbins, C. J., Bates, K., Benanto, J., et al. (2026). Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. Applied Immunohistochemistry & Molecular Morphology , 34(3), 143-154. https://doi.org/10.1097/pai.0000000000001311

### BibTeX

@article{he2026quantitative,
title = {Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score},
author = {He, M. and Chan, N. N. N. and Liu, M. and Robbins, C. J. and Bates, K. and Benanto, J. and others},
journal = {Applied Immunohistochemistry & Molecular Morphology},
volume = {34},
number = {3},
pages = {143--154},
year = {2026},
doi = {10.1097/pai.0000000000001311},
pmid = {41709478}
}

TROP2 is a protein found on most breast tumors, and a new class of antibody-drug conjugate therapies is aimed squarely at it. Yet only about a third of patients respond, even though roughly nine in ten breast cancers carry TROP2 — so a reliable way to measure how much is present could help decide who will benefit.

This study built two assays that report TROP2 as an actual concentration rather than a subjective score. One reads a fluorescent signal and the other a brown-stain signal, and both are calibrated against known amounts of protein using mass spectrometry.

Tested across hundreds of breast cancer samples and checked against the readings of five pathologists, the assays matched expert scoring while resolving finer differences, particularly in tumors carrying high levels of TROP2.

[Read publication at Applied Immunohistochemistry & Molecular Morphology](https://doi.org/10.1097/pai.0000000000001311)

## Key findings

- Two mass-spectrometry-calibrated TROP2 assays reached defined analytical limits. The quantitative immunofluorescence (QIF) and quantitative hematoxylin-DAB (QH-DAB) assays convert imaging signal to absolute TROP2 concentration (amol/mm 2 ) using cell-line standards, giving limits of detection of 90 and 667 amol/mm 2 and limits of quantification of 272 and 2021 amol/mm 2 , with standard-curve R 2 of 0.99.

- A broad TROP2 dynamic range emerged across two Yale breast-cancer cohorts. Applied to a 264-case serial breast cancer cohort and a 100-case triple-negative breast cancer cohort from Yale New Haven Hospital, the assays resolved a wide range of TROP2 expression, with the QIF assay reading up to roughly 10,000 amol/mm 2 before saturation.

- Quantitative measurement agreed with pathologist H-scores while adding sensitivity. Across 68 breast cancer biopsies read by 5 certified pathologists, the QIF and QH-DAB values tracked the manual H-scores, but the quantitative assays showed higher sensitivity and less subjectivity, with H-scores saturating in TROP2-high cases.

## CyteFinder II HT in the methods

“Fluorescent slides were scanned using the Rarecyte Cytefinder II HT (Rarecyte, Seattle, WA), an automated widefield fluorescence slide scanner at 20× magnification with fixed exposure times for each channel.”

— He et al., Applied Immunohistochemistry & Molecular Morphology (2026), Methods, “Image Acquisition, Quantification, and H-Score Evaluation”

## Why it matters for CyteFinder II HT users

If you are weighing the CyteFinder II HT for a quantitative tissue assay, look at what the imaging step was asked to carry here. The claim the authors needed to support is numerical: not whether TROP2 is present, but how much, in absolute units per unit area. That kind of measurement only holds if the imaging is reproducible enough to sit under a calibration curve, which is why the assay depended on scanning every slide at a fixed magnification with fixed exposure times for each channel. Here the CyteFinder II HT scanned the fluorescence slides at 20×, and the resulting images fed an open QuPath-based analysis tool rather than a closed one. Two points carry over to your own workflow. Consistent per-channel exposures are what let a raw signal be converted to a protein concentration across hundreds of samples. And because the scanner writes standard image files, the downstream quantification stays a choice you make, not one the instrument makes for you.

[Back to all resources](/#library)
## Related resources
[Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) CyteFinder Clinical Cancer Research 2025
### Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213210/) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12083604/) CyteFinder medRxiv 2025
### Validation and Prospective Testing of a High Sensitivity, Quantitative Analytic Assay for HER2 on Histopathology Slides
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12083604/) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226049/) CyteFinder JCI Insight 2025
### Imlunestrant, a next-generation oral SERD, overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12226049/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025
### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/38181b42312e8912f6bb4f99b8498af06b1b9774.pdf) CyteFinder 2025
### Elevated Levels of Circulating Endothelial Cells in Pregnancies Complicated by Pre-Eclampsia and/or Fetal Growth Restriction
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/38181b42312e8912f6bb4f99b8498af06b1b9774.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162492/) CyteFinder npj Breast Cancer 2024
### Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11162492/) [Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) CyteFinder 2024
### New Discoveries in HER2 Detection: A Novel Method of Multimodal Detection of HER2 from a Single Tube of Blood
[Watch Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11018817/) CyteFinder Nature Communications 2024
### Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11018817/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) CyteFinder 2024
### Development and analytic validation of an ARv7 / PSMA dual biomarker circulating tumor cell assay
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) CyteFinder 2024
### Development and validation of an assay for the characterization of SSTR2 expression on CTCs from liquid biopsies
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/16a6f80f656d101bdd81726d83d0246d16619b83.pdf) CyteFinder 2024
### A Novel Method for Placental Evaluation: Isolation of Intact Circulating Trophoblast Cells from Maternal Circulation
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/16a6f80f656d101bdd81726d83d0246d16619b83.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10761880/) CyteFinder npj Breast Cancer 2024
### Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC10761880/)